Radial Access a Toss Up for Stroke Thrombectomy
PHOENIX — Transradial access for endovascular thrombectomy was noninferior to standard transfemoral access, a single-center randomized trial showed. The rate of recanalization success was 87.9% (51 of 58) with transfemoral access and 96.6% (56 of 58) with transradial access, with an adjusted risk difference of 3.3% and a lower bound of -5.0% that fell within […]
Linezolid ‘Not Recommended’ to Treat Early Syphilis
Linezolid failed to meet noninferiority criteria when compared with standard benzathine penicillin G (BPG) in the treatment of early syphilis, according to findings of the randomized, controlled Trep-AB Study of cisgender men. Only 70% of trial participants with early syphilis who were treated with linezolid were cured, compared with 100% of participants treated with penicillin, […]
Cryobiopsy and Forceps Biopsy Go Head-to-Head for Diagnosing Lung Lesions
As a supplement to standard needle aspiration for diagnosing lung lesions, cryobiopsy was no better than forceps biopsy for producing a definite diagnosis in a randomized trial, but the tissue-freezing procedure was less time-consuming and did produce biopsy samples more suitable to molecular testing. Tested alone, the diagnostic yield was higher with mediastinal cryobiopsy versus […]
SBRT Added to Standard Tx Boosts Outcomes in Oligometastatic Prostate Cancer
Combining stereotactic body radiation therapy (SBRT) with standard systemic therapy yielded significant increases in the rates of biochemical response and progression-free survival (PFS) in patients with oligometastatic castrate-resistant prostate cancer (CRPC), the phase II randomized ARTO trial showed. In a cohort of 157 patients at 6 months after the start of treatment, biochemical response was […]
Adding Regorafenib in First-Line ‘Promising’ in Gastric Cancer
Adding regorafenib (Stivarga) to a standard first-line chemoimmunotherapy regimen for HER2-negative metastatic esophagogastric cancer demonstrated “promising” activity in a single-arm phase II study, according to researchers. Among 35 evaluable patients treated with the tyrosine kinase inhibitor (TKI) plus nivolumab (Opdivo) and FOLFOX chemotherapy, 25 (71%, 95% CI 54-85) remained progression free at 6 months, thus […]
Older Surgical Procedure for Pelvic Prolapse Repair Prevails in Randomized Trial
A long-time surgical standard for pelvic organ prolapse repair prevailed in a comparison against a newer technique that currently predominates in some parts of the world. Sacrospinous hysteropexy failed to meet noninferiority criteria versus the Manchester procedure for the primary composite outcome of treatment success, with the latter achieving success in 87.3% of patients compared […]
Hemodiafiltration Reduced Dialysis Mortality in Kidney Failure
High-dose hemodiafiltration improved survival compared with standard hemodialysis for patients with kidney failure resulting in the need for kidney-replacement therapy, according to the randomized CONVINCE trial. High-dose hemodiafiltration cut all-cause mortality to 17.3% compared with 21.9% on conventional high-flux hemodialysis over a median 30 months of follow-up (HR 0.77, 95% CI 0.65-0.93), reported researchers led […]
New Antiviral Option for CMV Prophylaxis After Kidney Transplant
Letermovir (Prevymis) proved noninferior to valganciclovir (Valcyte), the standard of care, in a clinical trial of cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients, researchers reported. In a phase III trial of 589 patients randomized 1:1 to receive either drug for up to 200 days post-transplant, the prevalence of CMV disease at 1 year was […]
FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia
Incorporating quizartinib into standard treatment for newly diagnosed acute myeloid leukemia (AML) followed by maintenance therapy with the investigational FLT3 inhibitor improved survival for patients with internal-tandem-duplication (ITD) mutations of FLT3, a placebo-controlled randomized trial showed. In the phase III study of over 500 patients undergoing standard induction and consolidation therapy, median overall survival (OS) […]
Nonimmunosuppressive Therapy Bests ARB for Cutting Proteinuira in IgA Nephropathy
AUSTIN, Texas — Once-daily sparsentan (Filspari) was better at reducing proteinuria than standard treatment in IgA nephropathy, according to a prespecified interim analysis of the PROTECT trial. By week 36 of treatment in the phase III study, patients on sparsentan saw a 49.8% reduction from baseline in urine protein-creatinine (UP/C) ratio compared with only a […]